Korean J Dermatol.  2011 Apr;49(4):382-384.

Erlotinib (Tarceva(R)) Induced Hair Abnormalities

Affiliations
  • 1Department of Dermatology, College of Medicine, Kyunghee University, Seoul, Korea. bellotte@hanmail.net

Abstract

Erlotinib is a low-molecular-weight quinazoline derivative that inhibits the activation of epidermal growth factor receptor (EGFR) tyrosine kinase through competitive binding of the adenosine triphosphate binding domain of the receptor. Patients undergoing anti-EGFR therapy frequently present with cutaneous reactions like a sterile follicular and pustular rash, xerosis, pruritus, paronychia, hair abnormalities and mucositis, which can cause serious discomfort and negatively affect the compliance with anti-EGFR therapy. We report here on an interesting case of hair abnormalities induced by erlotinib (Tarceva(R)) and this presented as eyelash lengthening and hair curling in a 62-year-old woman.

Keyword

Epidermal growth factor receptor inhibitor; Erlotinib; Hair abnormalities

MeSH Terms

Adenosine Triphosphate
Binding, Competitive
Compliance
Exanthema
Female
Hair
Humans
Middle Aged
Mucositis
Paronychia
Polyphosphates
Protein-Tyrosine Kinases
Pruritus
Quinazolines
Receptor, Epidermal Growth Factor
Erlotinib Hydrochloride
Adenosine Triphosphate
Polyphosphates
Protein-Tyrosine Kinases
Quinazolines
Receptor, Epidermal Growth Factor
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr